Fig. 4.

Changes in PPARγ expression do not account for glycaemia difference in the PIO-treated Hq mice.

(A) Western blot analysis of PPARγ in the skeletal muscle of 6 month-old untreated and treated WT and Hq mice. VDAC was indicated as a loading control. (B) Similar analysis performed on a set of untreated WT and Hq mice, and on PIO-treated animals presented according to their normal (normoglyc) or low glycaemia (hypoglyc). Numbers on the left panels refer to mouse numbering as in (Fig. 3A). (C) PPARγ, ratioed to VDAC, in untreated (black open squares) and 5 months PIO-treated (green open squares) 6 month-old WT, and in untreated (black circles) and 5 months PIO-treated (green circles) 6 month-old Hq mice. (D) PPARγ, ratioed to VDAC, in untreated 6 month-old WT (black open squares) and Hq (black circles) mice, and in 5 months PIO-treated Hq animals pooled according to their glycaemia, low (green filled crosses) or similar to WT (green open crosses). Biochemical analyses and statistical tests as described under Materials and Methods.